Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma

Prospective, Randomized, Multicenter Trial on the Antiproliferative Effect of Lanreotide, Interferon Alfa, and Their Combination for Therapy of Metastatic Neuroendocrine Gastroenteropancreatic Tumors—The International Lanreotide and Interferon Alfa Study Group

Siegbert Faiss, Ulrich‐Frank Pape, Michael Böhmig et al. · Journal of Clinical Oncology · 2003 · 500 citations

Medicine, Oncology, Pharmacotherapy +17

Carcinoid tumors: Analysis of prognostic factors and survival in 301 patients from a referral center

Eva Tiensuu Janson, Lars Holmberg, Mats Stridsberg et al. · Annals of Oncology · 1997 · 458 citations

Medicine, Oncology, Surgery +14

Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization

Francesco Panzuto, S. Nasoni, Massimo Falconi et al. · Endocrine Related Cancer · 2005 · 396 citations · Full text

Medicine, Oncology, Surgery +17

Epidemiology of Neuroendocrine Tumours

Babs G. Taal, Otto Visser · Neuroendocrinology · 2004 · 384 citations

Medicine, Endocrinology, Oncology +15

Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours.

R. Arnold, Michael Trautmann, W. Creutzfeldt et al. · Gut · 1996 · 345 citations · Full text

Medicine, Oncology, Pharmacology +14